Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase in B cell lymphomas

Autor/innen

  • C. Lopez
  • N. Schleussner
  • S.H. Bernhart
  • K. Kleinheinz
  • S. Sungalee
  • H.L. Sczakiel
  • H. Kretzmer
  • U.H. Toprak
  • S. Glaser
  • R. Wagener
  • O. Ammerpohl
  • S. Bens
  • M. Giefing
  • J.C.G. Sanchez
  • G. Apic
  • D. Hubschmann
  • M. Janz
  • M. Kreuz
  • A. Mottok
  • J.M. Müller
  • J. Seufert
  • S. Hoffmann
  • J.O. Korbel
  • R.B. Russell
  • R. Schule
  • L. Trumper
  • W. Klapper
  • B. Radlwimmer
  • P. Lichter
  • R. Kuppers
  • M. Schlesner
  • S. Mathas
  • R. Siebert

Journal

  • Haematologica

Quellenangabe

  • Haematologica

Zusammenfassung

  • Histone methylation-modifiers, like EZH2 and KMT2D, are recurrently altered in B-cell lymphomas. To comprehensively describe the landscape of alterations affecting genes encoding histone methylation-modifiers in lymphomagenesis we investigated whole genome and transcriptome data of 186 mature B-cell lymphomas sequenced in the ICGC MMML-Seq project. Besides confirming common alterations of KMT2D (47% of cases), EZH2 (17%), SETD1B (5%), PRDM9 (4%), KMT2C (4%), and SETD2 (4%) also identified by prior exome or RNAseq studies, we here unravel KDM4C in chromosome 9p24, encoding a histone demethylase, to be recurrently altered. Focal structural variation was the main mechanism of KDM4C alterations, which was independent from 9p24 amplification. We identified KDM4C alterations also in lymphoma cell lines including a focal homozygous deletion in a classical Hodgkin lymphoma cell line. By integrating RNAseq and genome sequencing data we predict KDM4C structural variants to result in loss-of-function. By functional reconstitution studies in cell lines, we provide evidence that KDM4C can act as tumor suppressor. Thus, we show that identification of structural variants in whole genome sequencing data adds to the comprehensive description of the mutational landscape of lymphomas and, moreover, establish KDM4C as putative tumor suppressive gene recurrently altered in subsets of B-cell derived lymphomas.


DOI

doi:10.3324/haematol.2021.280005